A Prospective Observational Study on Outcomes of Hepatitis B, Hepatitis C Patients in Gastroenterology Department of Tertiary Care Hospital

Abstract

Oral direct-acting antiviral (DAA) regimens for chronic hepatitis C virus (HCV) infection have considerably increased treatment efficacy, with sustained virological response (SVR) rates of greater than 95% for patients who are infected with HCV. HBV/HCV coinfection, however, is more complicated than infection with either HBV or HCV alone. We assessed the rate of HBV reactivation both during and three months after therapy in patients with HCV/HBV and the SVR rate at 12 weeks treatment with DAAs. 361 (95.5%) of the patients who were included in the study had SVR. Failure to attain SVR was predicted by older age, low platelet count, high blood creatinine, and higher liver stiffness value evaluated by fibroscan. In comparison to those without HBV reactivation, the baseline values for the 13 patients (4%) with HBV reactivation were much higher for ALT, serum creatinine, and HCV RNA virus load. DAA treatment for HCV/HBV coinfection resulted in high SVR in the patients. But it's critical to be mindful of the possibility of HBV reactivation both during and after DAA treatment